Noninvasive markers of liver fi brosis in patients with primary biliary cirrhosis (PBC) are needed for predicting disease progression. As the Wisteria fl oribunda agglutinin-positive Mac-2-binding protein (WFA + -M2BP) was recently established as a liver fi brosis glycobiomarker in chronic hepatitis C, we assessed its effi cacy in evaluating liver fi brosis stage and disease progression in PBC.
INTRODUCTION
Primary biliary cirrhosis (PBC) is an autoimmune liver disease characterized by portal infl ammation and immune-mediated destruction of intrahepatic bile ducts that oft en leads to cirrhosis and liver failure ( 1, 2 ) . Th e course of PBC is highly variable, ranging from several years for rapidly progressive cases to a normal life expectancy in a proportion of asymptomatic patients. Th e diagnosis of PBC is based on established criteria that include a cholestatic serum biochemical liver test, positivity for antimitochondrial antibody, and liver biopsy fi ndings ( 3 ) . Although liver biopsy is the gold standard to assess the degree of liver fi brosis, it is oft en limited by invasiveness and pain, sampling error, and interobserver disparity ( 4, 5 ) . Biopsy of the liver may be indicated in a small proportion of patients in whom diagnostic features are atypical for PBC ( 6 ) . As severe fi brosis and cirrhosis are generally related to a poor outcome ( 2 ) , simple and reliable noninva-
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METHODS

Subjects
A total of 303 patients were diagnosed as having PBC between January 1981 and June 2014 at the Shinshu University Hospital or its affi liated institutions. Among them, 166 patients were excluded from this retrospective analysis for the following reasons: (i) no liver histology data ( n =84); (ii) no stored serum from before ursodeoxycholic acid (UDCA) administration ( n =62); (iii) other chronic liver diseases, such as hepatitis B, hepatitis C, or nonalcoholic steatohepatitis ( n =15); and (iv) follow-up<6 months ( n =5). Th e remaining 137 uniformly Japanese patients were enrolled in the present study. Th e characteristics of the 137 biopsied patients and 84 non-biopsied patients are summarized in Supplementary Table 1 online . Th e diagnosis of PBC was on the basis of criteria from the American Association for the Study of Liver Diseases ( 3 ). All patients were treated with UDCA (10-13 mg/kg per day). Forty-fi ve healthy subjects with normal liver function tests served as controls. In addition, 40 Japanese patients with type 1 autoimmune hepatitis were adopted as comparison cases having another autoimmune liver disease. All patients and controls were negative for hepatitis B surface antigen and antibodies to hepatitis B core antigen, hepatitis C virus, and the human immunodefi ciency virus. Patients who exhibited evidence of other liver diseases during follow-up, such as alcoholic or non-alcoholic liver diseases, were excluded from the cohort. Th is study was conducted in accordance with the principles of the 1975 Declaration of Helsinki. Th e protocol was reviewed and approved by the institutional ethics committee. Serum samples were obtained at the time of liver biopsy before UDCA treatment and stored at −30 °C until testing.
Laboratory testing
All laboratory data were obtained on the same day as the liver biopsy. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, γ -glutamyltransferase, and other relevant biochemical tests were performed using the standard methods. Four additional surrogate blood indices of liver fi brosis were assessed at enrollment: AST-to-platelet ratio (APRI), FIB-4 index, AST/ALT ratio, and Forn's index. APRI ( 13 ) , FIB-4 index ( 14 ) , and Forn's index ( 15 ) were calculated according to published formulae. Th e Mayo clinic risk score for PBC was also tested as a potential surrogate marker of liver fi brosis ( 16 ) . Antinuclear antibody titer was determined by immunofl uorescence using HEp-2 cells, whereby a titer of 1:80 or greater was considered as positive ( 17 ) . Serum antimitochondrial antibody, which is specifi c for the pyruvate dehydrogenase complex-E2 component, was measured using an enzyme-linked immunosorbent assay. An index of greater than 7 was considered to be a positive result ( 18 ) .
Liver biopsy and histological evaluation
Liver biopsies were performed by percutaneous sampling of the right lobe with a 14-gauge needle in all patients, but seven before administration of UDCA. All biopsies were 1.5 cm or more in length. Formalin-fi xed and paraffi n-embedded specimens were prepared and used for histopathological studies. Sections measuring 4 μ m were cut from each paraffi n block and stained with hematoxylin and eosin, periodic acid-Schiff aft er diastase digestion, and Azan-Mallory staining. For the seven patients who did not undergo liver biopsy, nodular liver laparoscopic fi ndings had already indicated defi nite cirrhosis. Histological stage was determined according to the classifi cation of Scheuer ( 19 ) . Liver fi brosis and necroinfl ammatory activity were judged using the METAVIR scoring system ( 20 ) , wherein signifi cant fi brosis was defi ned as ≥F2, severe fi brosis as ≥F3, and cirrhosis as F4. Th e degree of bile duct loss (0, absent; 1, 1/3 of portal tract; 2, 2/3 of portal tract; and 3, >2/3 of portal tract) was evaluated as described by Nakanuma et al. ( 21 ) Th e investigators (AM, ET) involved in this part of the study were blinded to the results of other portions.
Measurement of WFA
+ -M2BP
WFA + -M2BP was quantifi ed on the basis of a lectin-antibody sandwich immunoassay using a fully automatic HISCL-5000 immunoanalyzer (Sysmex Co., Hyogo, Japan) ( 7 
Statistical analysis
Categorical variables were compared using the χ 2 or Fisher's exact test, as appropriate, and continuous variables were compared with the Mann-Whitney U -test. Spearman's rank order correlations were used to evaluate serum WFA + -M2BP levels with clinical features. Th e diagnostic performance of WFA + -M2BP was determined in terms of sensitivity, specifi city, positive, and negative predictive values, and area under the receiver operating characteristic curve (AUC). Optimal cutoff values were determined using the Youden index. Comparison of paired AUCs and 95% confi dence intervals was carried out using the nonparametric Delong test ( 23 ) .
Clinical outcome as of June 2014 was recorded as either liverrelated death, liver transplantation, or liver decompensation, such as ascites, esophageal varices, hepatic encephalopathy, hepatocellular carcinoma, or total serum bilirubin level above 3 mg/dl. Th e Kaplan-Meier method and log-rank test were used to estimate the survival rate of patients. Multivariate analysis was performed using the Cox proportional hazards model with stepwise method. A P <0.05 was considered to be signifi cant. Statistical analyses were performed using the IBM SPSS Statistics 21.0 (IBM, Chicago, IL) and StatFlex ver. 6.0 (Artech, Osaka, Japan) soft ware.
RESULTS
Baseline clinical characteristics of patients
Th e clinical profi le of the experimental patient cohort is shown in Table 1 . Th e median age was 57 years with a female predominance (84%). Th e median follow-up was 7.7 years (interquartile range (IQR), 3.7-13. Receiver operating characteristic curve analysis was performed to determine the diagnostic accuracy of WFA + -M2BP for each stage of fi brosis in PBC. Th e calculated AUC, optimal cutoff value, sensitivity, specifi city, positive predictive value, and negative predictive value for each fi brosis stage are listed in Table 3 . AUCs were 0.883, 0.979, 0.933, and 0.965 for ≥F1, ≥F2, ≥F3, and F4, respectively. Th e optimal cutoff values that best predicted fi brosis stages ≥F1, ≥F2, ≥F3, and F4 were 0.7, 1.0, 1.4, and 2.0, respectively. Overall, WFA + -M2BP was found to be of high reliability for the diagnosis of signifi cant fi brosis, severe fi brosis, and cirrhosis.
We next performed univariate and multivariate analyses of factors associated with the presence of signifi cant fi brosis (≥F2; Supplementary Table 3 ) . Th e variables of total protein, ALT, AST, alkaline phosphatase, γ -glutamyltransferase, bilirubin, IgM, IgG, antimitochondrial antibody positivity, WFA + -M2BP>1.0, FIB-4 index>1.8, APRI>0.5, AST/ALT ratio>1.1, and Forn's index>6.9 were signifi cantly higher in the signifi cant fi brosis group than in the nonsignifi cant fi brosis group, whereas platelet count and albumin were signifi cantly lower in the signifi cant fi brosis group. Among these, IgG, antimitochondrial antibody positivity, WFA + -M2BP, and Forn's index were independent variables associated with signifi cant fi brosis according to multivariate logistic regression analysis.
Comparison of fi brosis marker AUCs
Th e receiver operating characteristic curves for WFA 
Prediction and risk factors of liver-related death, transplantation, and liver decompensation at diagnosis
The results of multivariate Cox regression analysis regarding factors associated with liver-related death or liver transplantation are shown in Table 4 and reveal WFA + -M2BP to be a significant predictor of these outcomes (hazard ratio 18.59; 95% confidence interval: 1.57-220.51, P =0.021). Moreover, in Kaplan-Meier estimates of liver-related death or transplantation at different WFA + -M2BP levels at diagnosis, the 10-year survival rate was 98.8% in patients with a low-risk WFA + -M2BP level (<2.0), vs. 59.1% in those with a high-risk WFA + -M2BP value (≥2.0; Figure 3 ). The cumulative patient survival rate between these two groups was significantly different (logrank test; P <0.001).
Multivariate Cox regression analysis regarding factors associated with liver decompensation is summarized in Table 5 and shows WFA + -M2BP to be a signifi cant predictor of this outcome (hazard ratio 11.55; 95% confi dence interval: 1.29-103.25, P =0.021). In Kaplan-Meier estimates of liver decompensation at diff erent WFA + -M2BP levels at diagnosis, the cumulative liver decompensation rate between the low-risk and high- 
DISCUSSION
Th is study clearly demonstrated that the WFA + -M2BP level in PBC was signifi cantly higher than that in healthy controls and increased with progression of fi brosis stage, which was in agreement with several studies regarding WFA + -M2BP and chronic hepatitis C ( 7, 10, 12 ) . As a liver fi brosis glycobiomarker with a fully automated immunoassay, WFA + -M2BP showed high specifi city and sensitivity in predicting signifi cant and severe fi brosis and cirrhosis in PBC. Histological liver data are generally not available for PBC because of the current standard of care minimizing the use of liver biopsy. Although our sample number, and especially the proportion of severe fi brosis (≥F3) and cirrhosis (F4) subjects, was relatively small, WFA + -M2BP appears to be a highly predictive fi brosis marker.
Our data confi rmed that the WFA + -M2BP assay was strongly associated with other noninvasive markers of fi brosis, as well with liver function tests. Furthermore, the assay was signifi cantly superior to the above fi brosis markers for identifying signifi cant (≥F2) and severe (≥F3) fi brosis. We witnessed two key features about the WFA + -M2BP assay that were distinct from the other published fi brosis markers. First, the AUC of the assay was as high as 0.98 for the F2 stage. In contrast, the AUCs of previously reported fi brosis markers gradually increased as fi brosis progressed. Th is suggests that the WFA + -M2BP assay may be a particularly good marker to diff erentiate early from signifi cant fi brosis ( Supplementary Table 2 ). Second, the range of the WFA + -M2BP serum thresholds observed in PBC patients was diff erent from those described in chronic hepatitis C ( 7,10,12 ) but were similar to those in non-alcoholic fatty liver disease ( 11 ), type 1 autoimmune hepatitis, and hepatitis B (Matsumoto and Umemura, personal communications). Th e reasons for lower WFA + -M2BP levels in PBC are unknown; however, individual cutoff values for each fi brosis stage should be determined for all liver diseases.
Although several fi brosis markers have been assessed for PBC ( 24, 25 ) , none have been established as surrogate markers in lieu of biopsy; only the enhanced liver fi brosis test, which includes serum hyaluronic acid, tissue inhibitor of metalloproteinase 1, and N-terminal propeptide of type III procollagen, has shown acceptable diagnostic accuracy for signifi cant fi brosis or cirrhosis ( 26 ) . As the enhanced liver fi brosis test was not performed in our cohort, a comparison of this marker with WFA + -M2BP is needed in the future. Transient elastography has also been described as one of the best noninvasive markers of liver fi brosis in PBC (27) (28) (29) . Whereas the diagnostic accuracy of this technique is high ( 29 ), 10-20% of transient elastography results are unreliable when the patient is obese or exhibits ascites ( 29, 30 ) . Operator skill aff ects its diagnostic success rate as well, indicating that there remain some limitations for transient elastography. As WFA + -M2BP combined with transient elastography may provide the highest accuracy for fi brosis assessment in PBC, we are now conducting prospective studies on dual testing.
Another important conclusion from this study is that WFA + -M2BP at diagnosis may be an independent prognostic factor for PBC. Several variables have been proposed to contribute to PBC progression, such as anti-gp210 antibody ( 31 ) and human leukocyte antigen haplotype ( 32 ) in the Japanese. Th e Mayo risk score appeared to be a good surrogate marker for predicting poor outcome in patients possessing symptomatic PBC with advanced fi brosis; however, risk score at diagnosis was not associated with adverse outcome in our cohort, possibly because of the large proportion of asymptomatic PBC and mild fi brosis. Very recently, a collaborative international multicenter study showed that levels of alkaline phosphatase and bilirubin at diagnosis to be prognostic markers for PBC in North American and European countries ( 33 ) . However, these parameters were not identifi ed as signifi cant factors related to an unfavorable outcome in the present investigation. Th is could be because of the small number of poor outcomes in this study or because it was underpowered to assess prognosis. Another explanation may be the diff erent ethnicities among study populations or the fact that the majority of our cohort was asymptomatic and exhibited mild fi brosis.
Lastly, we noticed that a high-risk WFA + -M2BP level (≥2.0) was associated with elevated long-term mortality in PBC. Th e identifi cation of PBC with a poor long-term outcome among patients treated with adequate doses of UDCA is an important issue in clinical practice as well as in the design of therapeutic trials; some patients with an incomplete response to UDCA develop a progressive disease condition that eventually leads to liver transplantation or death from liver-related causes. A number of prognostic models following the UDCA treatment have been shown to serve as independent predictors of transplant-free and overall survival ( 33-39 ). Zhang et al. ( 40 ) demonstrated that the biochemical responses at 6 months could represent those at 1 year aft er the UDCA therapy. As our aim was to estimate the prognosis of PBC at enrollment, the biochemical response to UDCA was not included in this investigation. Another report has shown that advanced histological stage determined by transient elastography at enrollment is also a strong prognostic indicator of PBC ( 29 ) . Our data suggest that evaluating WFA + -M2BP at entry is an easy and useful tool not only for predicting fi brosis stage in PBC, but also for estimating prognosis.
Th e limitations of this study are its retrospective nature and lack of a validation cohort despite a long median follow-up period of 7.7 years. In addition, only 9 (7%) of our 137 patients experienced liver-related death or transplantation. As repeated liver biopsies during follow-up were not conducted, the actual correlations between the changes in WFA + -M2BP and fi brosis could not be determined. Future prospective trials in larger cohorts that include various ethnicities are required for the WFA + -M2BP assay.
In conclusion, this study demonstrated the accuracy and usefulness of WFA + -M2BP for the assessment of liver fi brosis in patients with PBC, which was consistent with recent results obtained for chronic hepatitis C. WFA + -M2BP appears to be a simple, reliable, and noninvasive method for evaluating fi brosis and predicting clinical outcome in PBC.
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